Femasys Past Earnings Performance
Past criteria checks 0/6
Femasys's earnings have been declining at an average annual rate of -20.1%, while the Medical Equipment industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 0.8% per year.
Key information
-20.1%
Earnings growth rate
74.0%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 0.8% |
Return on equity | -303.3% |
Net Margin | -1,436.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry?
Oct 31Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now
Jul 05Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?
Apr 03Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation
Sep 27Femasys commercially launches Femcerv for cervical cancer screening
Sep 29Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M
Aug 10We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully
May 22Femasys: Revolutionizing Female Reproduction
Jul 16Revenue & Expenses Breakdown
How Femasys makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1 | -18 | 10 | 8 |
30 Jun 24 | 1 | -17 | 9 | 8 |
31 Mar 24 | 1 | -15 | 8 | 7 |
31 Dec 23 | 1 | -14 | 8 | 7 |
30 Sep 23 | 1 | -13 | 7 | 6 |
30 Jun 23 | 1 | -12 | 6 | 6 |
31 Mar 23 | 1 | -11 | 6 | 6 |
31 Dec 22 | 1 | -11 | 6 | 6 |
30 Sep 22 | 1 | -11 | 6 | 6 |
30 Jun 22 | 1 | -10 | 5 | 5 |
31 Mar 22 | 1 | -9 | 5 | 5 |
31 Dec 21 | 1 | -8 | 4 | 4 |
30 Sep 21 | 1 | -7 | 4 | 4 |
30 Jun 21 | 1 | -6 | 3 | 4 |
31 Mar 21 | 1 | -7 | 3 | 4 |
31 Dec 20 | 1 | -7 | 3 | 4 |
31 Dec 19 | 1 | -11 | 5 | 7 |
Quality Earnings: FEMY is currently unprofitable.
Growing Profit Margin: FEMY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FEMY is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare FEMY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FEMY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15%).
Return on Equity
High ROE: FEMY has a negative Return on Equity (-303.25%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/29 12:52 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Femasys Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Keay Nakae | Chardan Capital Markets, LLC |
Emily Bodnar | H.C. Wainwright & Co. |
Catherine Novack | JonesTrading Institutional Services, LLC |